This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duch, D. S. Articles by Nichol, C. A. Search for Related Content PubMed PubMed Citation Articles by Duch, D. S. Articles by Nichol, C. A.

Biochemical and Chemotherapeutic Studies on 2,4-Diamino-6-(2,5-dimethoxylbenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a Novel Lipid-soluble Inhibitor of Dihydrofolate Reductase

Department of Medical Biochemistry, Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709

The lipophilic diaminopyridopyrimidine BW 301U (2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine) is as active as methotrexate as an inhibitor of dihydrofolate reductase and mammalian cell growth. This compound was selected from among related pyridopyrimidines and other lipid-soluble diaminoheterocyclic compounds as having the most favorable combination of properties as a potent inhibitor of dihydrofolate reductase with minimal effects on histamine metabolism. In contrast to methotrexate, entry of BW 301U into cells is rapid and is not temperature dependent, indicating passage across cell membranes by diffusion. There is no competition between BW 301U and leucovorin (folinic acid) for uptake into Sarcoma 180 cells in culture. When BW 301U is added to culture medium, deoxyuridine incorporation ceases within the first few min, and this inhibition persists when cells are transferred to drug-free medium. Both leucovorin and thymidine are required to protect cells in culture from the cytotoxicity of BW 301U. The effect on thymidine biosynthesis appears to be indirect since BW 301U is inactive as an inhibitor of thymidylate synthetase. Hypoxanthine and thymidine restore growth by only 50% in cultures containing BW 301U, and complete restoration of growth requires the further addition of adenosine and either uridine or cytidine to the medium. In vivo, BW 301U is active against Walker 256, L1210, P388, Sarcoma 180, and Ehrlich ascites tumors.

¹ To whom requests for reprints should be addressed.

Received 1/24/82. Accepted 7/23/82.

This article has been cited by other articles:

				Y. Kaufman, I. Ifergan, L. Rothem, G. Jansen, and Y. G. Assaraf Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss Blood, April 15, 2006; 107(8): 3288 - 3294. [Abstract] [Full Text] [PDF]

				M. J. Barnes, E. J. Estlin, G. A. Taylor, G. W. Aherne, A. Hardcastle, J. J. McGuire, J. A. Calvete, J. Lunec, A. D. J. Pearson, and D. R. Newell Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of de Novo Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines Clin. Cancer Res., September 1, 1999; 5(9): 2548 - 2558. [Abstract] [Full Text] [PDF]

				H. Sprecher, H. M. Barr, J. I. Slotky, M. Tzukerman, G. D. Eytan, and Y. G. Assaraf Alteration of Mitochondrial Gene Expression and Disruption of Respiratory Function by the Lipophilic Antifolate Pyrimethamine in Mammalian Cells J. Biol. Chem., September 1, 1995; 270(35): 20668 - 20676. [Abstract] [Full Text] [PDF]